Targovax Logo

Targovax

ISIN: NO0010689326 | Ticker: TRVX | LEI: 5967007LIEEXZXFYNS31
Sector: Health CareSub-Industry: Biotechnology
Country: Norway

About Targovax

Company Description

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Year founded

2010

Served area

Worldwide

Headquarters

Vollsveien 19, 1366 Lysaker – Norway

Financial statements

Download as Excel
Line item in (nok) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 520,740,000.00 565,271,000.00 100,414,000.00
Noncurrent Assets N/A 393,559,000.00 374,382,000.00 6,302,000.00
Property Plant And Equipment N/A 179,000.00 111,000.00 5,035,000.00
Current Assets N/A 127,180,000.00 190,889,000.00 94,112,000.00
Trade And Other Current Receivables N/A 4,859,000.00 9,207,000.00 28,097,000.00
Cash and cash equivalents 70,429,000.00 122,321,000.00 181,682,000.00 66,015,000.00
Equity And Liabilities N/A 520,740,000.00 565,271,000.00 100,414,000.00
Equity 296,955,000.00 372,588,000.00 417,726,000.00 2,566,000.00
Issued Capital N/A 8,653,000.00 18,833,000.00 18,847,000.00
Retained Earnings N/A -778,136,000.00 309,289,000.00 -123,672,000.00
Share Premium N/A 1,046,476,000.00 0.00 N/A
Other Reserves N/A 52,684,000.00 59,620,000.00 63,780,000.00
Noncurrent Liabilities N/A 122,495,000.00 110,212,000.00 57,433,000.00
Deferred Tax Liabilities N/A 62,047,000.00 59,314,000.00 N/A
Longterm Borrowings N/A 57,881,000.00 49,523,000.00 57,433,000.00
Current Liabilities N/A 25,656,000.00 37,333,000.00 40,415,000.00
Trade And Other Current Payables To Trade Suppliers N/A 5,196,000.00 8,103,000.00 11,383,000.00
Current Payables On Social Security And Taxes Other Than Income Tax N/A 3,428,000.00 3,203,000.00 3,074,000.00
Other Current Liabilities N/A 12,589,000.00 17,134,000.00 19,971,000.00
Line item in (nok) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 624,000.00 0.00 10,002,000.00
Other Revenue 624,000.00 0.00 10,002,000.00
Employee Benefits Expense 43,090,000.00 48,386,000.00 52,238,000.00
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 3,735,000.00 1,309,000.00 392,673,000.00
Other Expense By Nature 12,658,000.00 8,466,000.00 11,454,000.00
Profit Loss From Operating Activities -103,901,000.00 -95,601,000.00 -493,591,000.00
Finance Income 596,000.00 245,000.00 3,360,000.00
Finance Costs 5,099,000.00 2,667,000.00 5,097,000.00
Profit Loss Before Tax -108,403,000.00 -98,023,000.00 -495,328,000.00
Income Tax Expense Continuing Operations -277,000.00 -52,000.00 -62,430,000.00
Profit (loss) -108,126,000.00 -97,971,000.00 -432,898,000.00
Line item in (nok) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -108,126,000.00 -97,971,000.00 -432,898,000.00
Adjustments For Finance Costs N/A 5,099,000.00 2,667,000.00 5,097,000.00
Adjustments For Sharebased Payments N/A 5,799,000.00 6,935,000.00 4,160,000.00
Interest Received Classified As Operating Activities N/A 596,000.00 245,000.00 536,000.00
Cash Flows From Used In Operating Activities N/A -110,793,000.00 -85,402,000.00 -108,841,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 70,000.00 0.00 4,935,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A N/A N/A 24,000.00
Cash Flows From Used In Investing Activities N/A -70,000.00 0.00 -4,959,000.00
Proceeds From Issuing Shares N/A 176,021,000.00 175,000,000.00 0.00
Proceeds From Borrowings Classified As Financing Activities N/A 5,555,000.00 0.00 N/A
Repayments Of Borrowings Classified As Financing Activities N/A 0.00 2,023,000.00 2,086,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,209,000.00 1,468,000.00 1,515,000.00
Interest Paid Classified As Financing Activities N/A 704,000.00 710,000.00 680,000.00
Cash Flows From Used In Financing Activities N/A 163,534,000.00 145,610,000.00 -4,328,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 52,671,000.00 60,208,000.00 -118,129,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -778,000.00 -848,000.00 2,462,000.00
Cash and cash equivalents 70,429,000.00 122,321,000.00 181,682,000.00 66,015,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

NO0010689326

LEI

5967007LIEEXZXFYNS31

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Oslo Børs

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.